58 completed, 21 terminated, 7 unknown, 6 active not recruiting. 95 Phase 2, 8 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 95 | Completed 58, Terminated 21, Unknown 7, Active not recruiting 6, Withdrawn 3 |
| Phase 1 | 8 | Terminated 4, Completed 2, Unknown 2 |
| Phase 3 | 2 | Completed 1, Unknown 1 |
Follow Sunitinib Malate: new trials by email Literature Review of Sunitinib Malate trials Research Report on Sunitinib Malate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC) Sunitinib Malate, TAS 102 - Colorectal Cancer, Metastasis | Phase 2 / Phase 3 | Unknown | Amsterdam UMC, location VUmc | 60 | 2019-10-01 | 2020-11-13 |
| A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD Drug: GB-102, Aflibercept - Neovascular Age-Related Macular Degeneration | Phase 2 | Completed | Graybug Vision | 56 | 2019-09-26 | 2022-01-19 |
| A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occlusion GB-102 - Diabetic Macular Edema, Retina Vein Occlusion | Phase 2 | Completed | Graybug Vision | 21 | 2019-09-11 | 2021-11-22 |
| Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer Laboratory Biomarker Analysis, Pembrolizumab, Sunitinib Malate - Thymic Carcinoma | Phase 2 | Active not recruiting | Dwight Owen | 9 | 2018-06-19 | 2026-08-06 |
| Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma Cabozantinib, Sunitinib Malate - Malignant Neoplasms of Urinary Tract, Renal Cell Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 32 | 2018-05-15 | 2026-07-16 |
| Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 152 | 2016-07-25 | 2025-01-13 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 6452 | 2015-08-17 | 2026-11-12 |
| A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population Sunitinib malate - Renal Cell Carcinoma | Phase 2 | Terminated | vghtpe user | 13 | 2015-08-12 | 2018-06-26 |
| Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma Sunitinib, Valproic Acid, Sunitinib Malate - Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size | Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 210 | 2014-11-19 | 2026-10-22 |
| Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC) Sunitinib, Questionnaire - Genitourinary Cancer, Kidney Cancer | Phase 2 | Completed | M.D. Anderson Cancer Center | 60 | 2014-08-01 | 2020-02-27 |
| Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Cabozantinib S-malate, Laboratory Biomarker Analysis, Sunitinib Malate - Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 157 | 2013-07-08 | 2021-02-11 |
| Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate - Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 41 | 2012-08-01 | 2022-06-07 |
| A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor sunitinib malate dose escalation, sunitinib malate - Gastrointestinal Stromal Tumors | Phase 2 | Completed | Pfizer | 6 | 2012-06-01 | 2019-03-27 |
| Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia Antitumor Drug Screening Assay, Dasatinib, Idelalisib - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia | Phase 2 | Terminated | OHSU Knight Cancer Institute | 12 | 2012-05-11 | 2021-11-04 |
| Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Diagnostic Laboratory Biomarker Analysis, Pharmacological Study, Sunitinib Malate - Childhood Cerebellar Anaplastic Astrocytoma, Childhood Cerebral Anaplastic Astrocytoma | Phase 2 | Completed | National Cancer Institute (NCI) | 30 | 2012-01-01 | 2015-08-27 |
| Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies Abiraterone Acetate, Prednisone, Sunitinib - Prostate Cancer | Phase 2 | Completed | M.D. Anderson Cancer Center | 190 | 2011-03-16 | 2025-01-27 |
| A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma Dacarbazine, Sunitinib - Metastatic Uveal Melanoma | Phase 2 | Completed | The Clatterbridge Cancer Centre NHS Foundation Trust | 124 | 2010-10-01 | 2019-10-29 |
| Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer sunitinib malate - Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer | Phase 2 | Completed | Case Comprehensive Cancer Center | 37 | 2010-08-18 | 2018-09-14 |
| Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma Everolimus, Sunitinib - Kidney Cancer | Phase 2 | Terminated | M.D. Anderson Cancer Center | 73 | 2010-08-01 | 2021-04-28 |
| Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer sunitinib malate, Placebo, transarterial chemoembolization - Liver Cancer | Phase 2 / Phase 3 | Completed | Federation Francophone de Cancerologie Digestive | 78 | 2010-07-01 | 2022-03-18 |
Showing 20 of 95. Sign in to see all of them.
Carcinoma, Renal Cell (24) · Kidney Neoplasms (13) · Breast Neoplasms (7) · Neoplasm Metastasis (7) · Urinary Bladder Neoplasms (7) · Prostatic Neoplasms (6) · Carcinoma, Hepatocellular (5) · Esophageal Neoplasms (4) · Liver Neoplasms (4) · Melanoma (4) · Ovarian Neoplasms (4) · Uveal Melanoma (4) · Astrocytoma (3) · Brain Neoplasms (3) · Breast Neoplasms, Male (3)
National Cancer Institute (NCI) (23) · M.D. Anderson Cancer Center (9) · Case Comprehensive Cancer Center (5) · Memorial Sloan Kettering Cancer Center (5) · H. Lee Moffitt Cancer Center and Research Institute (3) · Pfizer (3) · University of Washington (3) · Federation Francophone de Cancerologie Digestive (2) · Graybug Vision (2) · OHSU Knight Cancer Institute (2) · US Oncology Research (2) · University of California, San Francisco (2) · Abramson Cancer Center at Penn Medicine (1) · Alliance for Clinical Trials in Oncology (1) · Amsterdam UMC, location VUmc (1)
United States (70) · Canada (10) · France (6) · United Kingdom (4) · Australia (3) · Netherlands (2) · South Korea (2) · Spain (2) · Taiwan (2) · Argentina (1) · Brazil (1) · Czechia (1) · Guam (1) · Italy (1) · Mexico (1)
Eric Jonasch, MD (3) · Robert J. Motzer, MD (3) · Amado Zurita, MD (2) · Dean F. Bajorin, MD (2) · Hope S. Rugo, MD (2) · Jonathan Strosberg, MD (2) · Alain Ravaud, MD, PhD (1) · Aminah Jatoi, MD (1) · Amit M Oza (1) · Arkadiusz Dudek, MD (1) · Brian I. Rini, MD (1) · Brian Rini (1) · Catherine Meyerle, MD (1)
PMID 33852135, PMID 37146227, PMID 19451429, PMID 19536893, PMID 19547919, PMID 20203173, PMID 20711632, PMID 20975250, PMID 21148613, PMID 21174224, PMID 21898376, PMID 22105611, PMID 22261812, PMID 22425095, PMID 22614181, PMID 22761653, PMID 23228446, PMID 23660867, PMID 24268852, PMID 24821582, PMID 24882554, PMID 25085632, PMID 25532471, PMID 25577718, PMID 25732163, PMID 25802238, PMID 26151457, PMID 26582660, PMID 26586415, PMID 27029034, PMID 27109549, PMID 27217543, PMID 27238653, PMID 28410911, PMID 28549224, PMID 29550566, PMID 29641297, PMID 29921512, PMID 31006038, PMID 31231785, PMID 31371341, PMID 31399500, PMID 31986451, PMID 32463741, PMID 32576496, PMID 32623479, PMID 33048619, PMID 33592176, PMID 34393061, PMID 35133871
P30CA008748 (4), U10CA031946 (4), N01CM62201 (3), N01CM62203 (3), P30CA043703 (3), U10CA180821 (3), N01CM62202 (2), P30CA014599 (2), U10CA027469 (2), 2008 (1), N01CM00038 (1), N01CM62205 (1), N01CM62206 (1), N01CM62207 (1), N01CM62209 (1)